Identifying blood and tissue markers for tumor hypoxia in head and neck and lung cancers
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
This study is trying to find new blood and tissue markers that show low oxygen levels in tumors to help people with head and neck and lung cancers understand their condition better and improve treatment outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Stanford, California) |
| Trial ID | NCT00568490 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify and confirm new blood and tissue markers that indicate tumor hypoxia, a condition linked to increased tumor spread and resistance to treatment in head and neck and lung cancers. The research focuses on validating the prognostic significance of specific proteins, such as osteopontin, and monitoring their levels during therapy and follow-up. Additionally, the study seeks to establish a gene and protein signature associated with hypoxia in affected patients.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically confirmed squamous cell carcinoma of the head and neck or non-small cell lung cancer.
Not a fit: Patients who do not have the specified types of cancer or who are unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools and treatment strategies for patients with head and neck and lung cancers.
How similar studies have performed: Other studies have explored tumor hypoxia markers, but this specific approach may provide novel insights into prognostic indicators.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck. * Able to sign a Stanford IRB approved consent form Exclusion criteria: * Refuse or unable to sign an IRB approved consent form. * Refuse to be contacted in the future for follow up.
Where this trial is running
Stanford, California
- Stanford University School of Medicine — Stanford, California, United States (Recruiting)
Study contacts
- Principal investigator: Quynh-Thu Le — Stanford University
- Study coordinator: Eyiwunmi Laseinde
- Email: Rad-onc-ccto@lists.stanford.edu
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.